News & Updates

Cefepime-taniborbactam (FTB) is significantly better than meropenem for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), according to results of the Cefepime Rescue with Taniborbactam in cUTI (CERTAIN-1) study presented at the recent ID Week 2022.

In the 6-year follow-up of the ECHELON-1 trial, a combination of the CD30-directed ADC* brentuximab vedotin and a chemotherapy (CT) regimen comprising doxorubicin, vinblastine, and dacarbazine (A+AVD), showed a survival advantage over a combination comprising the same CT regimen plus bleomycin (ABVD) in patients with previously untreated stage III or IV Hodgkin’s lymphoma (HL).

Treatment with tocilizumab leads to better suppression of joint erosion progression as compared to etanercept in patients with rheumatoid arthritis (RA), reports a recent study.

The use of vedolizumab in the treatment of older patients with inflammatory bowel disease (IBD) appears to not only pose a higher risk of treatment failure but also offer no significant safety advantage when compared with tumour necrosis factor (TNF) antagonists, according to a study.

Sequential intravesical valrubicin and docetaxel prove to be an effective salvage treatment for patients with recurrent nonmuscle-invasive bladder cancer (NMIBC), a study has shown.

A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.